Testing a new drug with infliximab in healthy volunteers
This study tests a new experimental drug called MT-201 when given with an existing medicine (infliximab) to healthy people. It helps doctors learn how the drugs work in the body and whether they are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 55 years old
- You are generally healthy with no major diseases
- If you are a woman, you cannot become pregnant (e.g., surgically sterilized)
- If you are a man, you must use effective birth control during the study
- You have not smoked or used nicotine products in the last 3 months
- You have not taken certain medications or donated blood recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called MT-201 to see if it is safe and how the body handles it. It is for healthy volunteers aged 19 to 55 who are willing to follow study rules.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This is the first human study of a new medication called MT-251. It is a safety study, so healthy volunteers are given either a single dose or multiple doses of the drug to see how the body handles it and if there are any side effects.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
This trial tests whether a person's genetic makeup affects how well infliximab works for treating Crohn's disease. It may help doctors predict which patients benefit most from this medication.
Hear when a new Healthy Volunteer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.